ROBOSENSE
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, has announced the launch of its first automotive-grade solid-state LiDAR perception solution for L4 autonomous driving, the RS-Fusion-P6 (P6). With advanced software and hardware support from RoboSense, the P6 provides precise and intelligent environmental perception capabilities, enabling autonomous vehicles to navigate through complex driving scenarios with ease, helping to reduce costs and increase efficiency, and promoting the rapid implementation of large-scale autonomous driving commercial operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005545/en/
RS-Fusion-P6 (Photo: Business Wire)
As an automotive-grade solid-state LiDAR perception solution, the P6 perfectly integrates hardware based on two-dimensional MEMS scanning technology and software based on artificial intelligence technology, fully demonstrating the leading level of RoboSense's core technologies in the areas of chips, hardware, and software.
RoboSense's RS-Fusion-P6 solution is designed to be flexible and scalable, making it suitable for a wide range of autonomous driving applications. It can be customized to meet the specific needs of different vehicle platforms and applications, providing a high level of performance and accuracy for all types of autonomous driving scenarios.
The P6 offers high-performance perception capabilities for full-scene environments from start to finish, making it ideal for a range of driving scenarios, including city streets, highways, and everything in between. Equipped with the four M-series solid-state LiDARs, the P6 offers dynamic switching and high-resolution long-distance detection capabilities, enabling intelligent perception over a 360-degree horizontal range, and allowing it to detect traffic conditions up to 200 meters away. The P6 can quickly process this data and provide feedback to the autonomous driving control center, allowing the vehicle to react in milliseconds to any changes in the driving environment.
P6 is equipped with RoboSense self-developed real-time point cloud perception software Perception. Under the intelligent processing of perception, P6 will be able to accurately process complex traffic environment information. Even in challenging driving scenarios, such as mixed traffic and inclement weather conditions, the P6 can accurately identify pedestrians, electric vehicles, cars, trucks, and other obstacles while tracking their speed, acceleration, and location. With this precise environmental perception data, autonomous vehicles equipped with the P6 can make accurate judgments and perform corresponding actions in real-time.
The launch of the P6 demonstrates RoboSense's deep understanding of the pain points in the autonomous driving industry. As the automotive industry continues to rapidly evolve, the P6 provides a reliable and high-performance perception solution that can help to accelerate the adoption of autonomous driving technology. With the P6, RoboSense further expands its product portfolio, which includes mechanical and solid-state LiDAR sensors, perception software, and integrated sensing solutions.
With its advanced perception capabilities and robust product portfolio, RoboSense is well-positioned to help accelerate the adoption of autonomous driving technology across a range of industries, including transportation, logistics, and mobility.
Full article of P6 in detail: https://www.robosense.ai/en/news-show-1690
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005545/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
